CY1109181T1 - Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων. - Google Patents

Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων.

Info

Publication number
CY1109181T1
CY1109181T1 CY20091100671T CY091100671T CY1109181T1 CY 1109181 T1 CY1109181 T1 CY 1109181T1 CY 20091100671 T CY20091100671 T CY 20091100671T CY 091100671 T CY091100671 T CY 091100671T CY 1109181 T1 CY1109181 T1 CY 1109181T1
Authority
CY
Cyprus
Prior art keywords
producers
trap
combinations containing
containing vegf
cancer combinations
Prior art date
Application number
CY20091100671T
Other languages
Greek (el)
English (en)
Inventor
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Eric Furfine
Jocelyn Holash
Jesse M Cedarbaum
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109181(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of CY1109181T1 publication Critical patent/CY1109181T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20091100671T 2004-12-03 2009-06-25 Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων. CY1109181T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP05824581A EP1824504B1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant vegf-trap et du 5fu ou un de ses derives

Publications (1)

Publication Number Publication Date
CY1109181T1 true CY1109181T1 (el) 2014-07-02

Family

ID=34954452

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20091100671T CY1109181T1 (el) 2004-12-03 2009-06-25 Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων.
CY2013017C CY2013017I1 (el) 2004-12-03 2013-05-13 Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων.
CY2013018C CY2013018I1 (el) 2004-12-03 2013-05-13 Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2013017C CY2013017I1 (el) 2004-12-03 2013-05-13 Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων.
CY2013018C CY2013018I1 (el) 2004-12-03 2013-05-13 Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων.

Country Status (25)

Country Link
US (3) US20060178305A1 (enExample)
EP (1) EP1824504B1 (enExample)
JP (1) JP4980236B2 (enExample)
KR (1) KR101313404B1 (enExample)
CN (1) CN101068564B (enExample)
AT (1) ATE426409T1 (enExample)
AU (1) AU2005311191C1 (enExample)
BR (1) BRPI0518700B8 (enExample)
CA (1) CA2586735C (enExample)
CY (3) CY1109181T1 (enExample)
DE (1) DE602005013568D1 (enExample)
DK (1) DK1824504T3 (enExample)
ES (1) ES2324233T3 (enExample)
FR (3) FR2878749B1 (enExample)
HR (1) HRP20090336T1 (enExample)
IL (1) IL183481A (enExample)
LU (2) LU92202I2 (enExample)
ME (1) ME01706B (enExample)
MX (1) MX2007006607A (enExample)
PL (1) PL1824504T3 (enExample)
PT (1) PT1824504E (enExample)
RS (1) RS50769B (enExample)
RU (1) RU2384344C2 (enExample)
SI (1) SI1824504T1 (enExample)
WO (1) WO2006059012A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
SI1824504T1 (sl) 2009-08-31
MX2007006607A (es) 2007-07-25
KR101313404B1 (ko) 2013-10-01
ATE426409T1 (de) 2009-04-15
AU2005311191C1 (en) 2015-04-30
LU92203I2 (fr) 2013-11-15
PL1824504T3 (pl) 2009-08-31
US20060178305A1 (en) 2006-08-10
HK1114769A1 (en) 2008-11-14
AU2005311191A1 (en) 2006-06-08
CY2013018I1 (el) 2020-05-29
AU2005311191B2 (en) 2011-12-08
CN101068564A (zh) 2007-11-07
CA2586735C (fr) 2014-08-12
FR13C0025I1 (fr) 2013-05-24
LU92203I9 (enExample) 2019-01-15
WO2006059012A1 (fr) 2006-06-08
EP1824504A1 (fr) 2007-08-29
DE602005013568D1 (de) 2009-05-07
LU92202I9 (enExample) 2019-01-15
FR13C0024I1 (fr) 2013-05-24
ES2324233T3 (es) 2009-08-03
BRPI0518700B1 (pt) 2020-02-11
RS50769B (sr) 2010-08-31
FR2878749A1 (fr) 2006-06-09
CN101068564B (zh) 2010-12-15
IL183481A0 (en) 2007-09-20
US8388963B2 (en) 2013-03-05
BRPI0518700A2 (pt) 2008-12-02
KR20070091130A (ko) 2007-09-07
CY2013017I1 (el) 2014-07-02
EP1824504B1 (fr) 2009-03-25
DK1824504T3 (da) 2009-07-20
ME01706B (me) 2010-08-31
US20090285841A1 (en) 2009-11-19
LU92202I2 (fr) 2013-11-15
CA2586735A1 (fr) 2006-06-08
RU2007123607A (ru) 2009-01-10
HRP20090336T1 (hr) 2009-07-31
JP4980236B2 (ja) 2012-07-18
PT1824504E (pt) 2009-06-25
IL183481A (en) 2013-09-30
FR2878749B1 (fr) 2007-12-21
US20130184205A1 (en) 2013-07-18
RU2384344C2 (ru) 2010-03-20
BRPI0518700B8 (pt) 2021-05-25
JP2008521866A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
CY1125289T1 (el) Αναστολεις kras g12c και μεθοδοι χρησης αυτων
CY1111675T1 (el) Αντικαρκινικοι συνδυασμοι που περιεχουν εναν ανασταλτικο παραγοντα toy vegf και ιρινοτεκανη
CY1120267T1 (el) Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
CY2013018I1 (el) Αντικαρκινικοι συνδυασμοι που περιεχουν vegf-trap και 5fu ή ενα εκ των παραγωγων αυτων.
CY1116571T1 (el) Ενωσεις φωσφορικου αμινοαλκυλο γλυκοζαμinιδιου και χρηση αυτων
CY1111902T1 (el) Χρηση ακυλοφωσφοχολινων σε συνδυασμο με αντινεοπλασματικα φαρμακα
CY1113188T1 (el) Τροποποιημενα fgf-21 πολυπεπτιδια και οι χρησεις τους
CY1118480T1 (el) Παραγωγα toy uk-2a
CY1117476T1 (el) Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
PT1244650E (pt) Derivados arilaminas e sua aplicacao como agentes anti-telomerase
CY1113160T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
ECSP088220A (es) Uso de dosis única de moléculas de unión específica cd20
CY1108444T1 (el) (πολυ)αμινοακεταμιδικα παραγωγα της επιποδοφυλλοτοξινης, η μεθοδος παρασκευης τους και οι εφαρμογες τους στη θεραπευτικη ως αντικαρκινικων παραγοντων
CY1108845T1 (el) Συνδυασμοι οι οποιοι περιεχουν εναν αντιδιαρροϊκο παραγοντα και μια εποθιλονη ή ενα παραγωγο εποθιλονης
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
AR010348A1 (es) Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen
CY1117499T1 (el) 5'-τριφωσφορικο ολιγονουκλεοτιδιο με κολοβωμενο ακρο και χρησεις εξ΄αυτου
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44
PT4255563T (pt) 5¿-o-fenilacetiluridina e uso terapêutico
AU306322S (en) Fibrous material